Navigation Links
CMC Biologics Wins 2013 CMO Leadership Award for Innovation, Quality and Reliability
Date:3/19/2013

SEATTLE and COPHENHAGEN, Denmark, March 19, 2013 /PRNewswire/ -- CMC Biologics, a global contract manufacturing organization known for its technical excellence in biopharmaceutical development and cGMP manufacture of protein based therapeutics, was recognized for innovation, quality and reliability by Life Science Leader at a prestigious ceremony at DCAT Week13 in New York last week.

(Logo: http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

"CMC Biologics is honored to receive this prestigious award and appreciate the recognition by Life Science Leader.  Our goal is to provide our customers with the highest standards of quality and reliability in both manufacturing and development, and which is the foundation of our customers' clinical and commercial success," said Claes Glassell , Chief Executive Officer. "The entire CMC Biologics' team is committed to continued improvement throughout our operations, and to continually innovate to advance biopharmaceutical manufacturing to the next level."

Bringing new pharmaceutical products to market is time consuming and costly, thereby having reliable and effective contract organizations to work with helps streamline that process. The Life Science Leader CMO Leadership awards are designed to honor top performers based on survey responses from thousands of industry executives, conducted by Nice Insight, and to better serve biopharmaceutical executives in their CMO selection process. These data will help companies focus on potential CMO partners who can handle their projects and are considered most reputable in the industry. For more information visit: www.cmoleadershipawards.com.

About CMC Biologics
CMC Biologics is leading the industry among CMO's in reliability, technical excellence, and quality – Right and On Time.  With facilities in the USA and Europe, the Company is a global CMO that provides fully integrated biopharmaceutical development and manufacturing solutions to clients around the world.  The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and commercial production.  The Company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing.  Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production.  CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes.  CMC Biologics is located in Copenhagen, Denmark; Seattle, Washington; and Berkeley, California. More detailed information can be found at www.cmcbiologics.com.


'/>"/>
SOURCE CMC Biologics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
2. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
3. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
6. Chinese Compulsory Immunization Program for Livestock Creates Massive Opportunity for Animal Vaccines and Biologics Developers
7. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
8. Pinnacle Biologics and INTERmedic Medical Devices announce strategic manufacturing and distribution agreement for cancer laser technology
9. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
10. Global Spinal Devices and Biologics Market 2011-2015
11. Synthetic Biologics Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... -- Clarifying Vision - Prospects and Developments ... Care What can be expected from the ... at the fastest rates? This visiongain report ... opportunities and prospects. ,Our 190-page report ... lucrative areas in the industry and the future market ...
(Date:5/23/2016)... 23, 2016 Experts from various ... Medicine and the role of technology in innovative ... The First International Conference of VPS-Penn Medicine opened in ... and presence of Sheikh Nahyan bin Mubarak Al Nahyan, Minister ... Medicine, which helps provide personalized medicine and tailor-made healthcare in ...
(Date:5/23/2016)... , May 23, 2016   Purdue Pharma ... into an agreement with Egalet Corporation and Acura ... As part of the agreement the companies will ... enable all three companies to develop and sell ... "This agreement reflects the commitment of Purdue ...
Breaking Medicine Technology:
(Date:5/24/2016)... , ... May 24, 2016 , ... Mental health watchdog ... the Church of Scientology and renowned professor of psychiatry Thomas Szasz, is continuing its ... “Psychiatry: An Industry of Death” exhibit in Atlanta, Georgia. The opening of the exhibit ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health ... adult hospital and expanded Children’s Hospital. Over 3,000 people looked on as the shovels ... out the event photo slidehsow. , During the program, Richard H. Hart, MD, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Backed ... data logger for each job, ensuring the best suited solution to meet regulatory ... data loggers at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Growing in ... growing trend, more gluten-free products are available and easily accessible. Whether someone chooses to ... to cater to a certain diet, King Kullen Grocery stocks their shelves with many ...
(Date:5/24/2016)... ... May 24, 2016 , ... The ... 9.3 million people, or 10% over last year, according to data in the ... group policies was comparatively stable, with a slight decrease in risk-based groups and ...
Breaking Medicine News(10 mins):